Premier Path Wealth Partners LLC Sells 135 Shares of Zoetis Inc. $ZTS

Premier Path Wealth Partners LLC cut its position in shares of Zoetis Inc. (NYSE:ZTS) by 2.4% in the second quarter, Holdings Channel.com reports. The institutional investor owned 5,414 shares of the company’s stock after selling 135 shares during the period. Premier Path Wealth Partners LLC’s holdings in Zoetis were worth $844,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Arkadios Wealth Advisors boosted its stake in Zoetis by 8.2% during the second quarter. Arkadios Wealth Advisors now owns 11,978 shares of the company’s stock valued at $1,868,000 after buying an additional 903 shares during the last quarter. Flagship Harbor Advisors LLC boosted its stake in Zoetis by 3.0% during the second quarter. Flagship Harbor Advisors LLC now owns 7,616 shares of the company’s stock valued at $1,188,000 after buying an additional 222 shares during the last quarter. Daymark Wealth Partners LLC boosted its stake in Zoetis by 8.6% during the second quarter. Daymark Wealth Partners LLC now owns 9,543 shares of the company’s stock valued at $1,488,000 after buying an additional 752 shares during the last quarter. Oarsman Capital Inc. boosted its stake in Zoetis by 8.3% during the second quarter. Oarsman Capital Inc. now owns 2,071 shares of the company’s stock valued at $323,000 after buying an additional 158 shares during the last quarter. Finally, Bank of Jackson Hole Trust boosted its stake in Zoetis by 8.8% during the second quarter. Bank of Jackson Hole Trust now owns 4,375 shares of the company’s stock valued at $682,000 after buying an additional 355 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Price Performance

Shares of ZTS stock opened at $143.77 on Friday. Zoetis Inc. has a 52-week low of $139.34 and a 52-week high of $183.11. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The firm has a market capitalization of $63.72 billion, a P/E ratio of 24.75, a P/E/G ratio of 2.31 and a beta of 0.90. The stock has a 50 day moving average price of $147.40 and a 200 day moving average price of $153.41.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same period last year, the company earned $1.56 EPS. Zoetis’s quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is currently 34.42%.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Piper Sandler increased their price target on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Argus reaffirmed a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. UBS Group lowered their price objective on Zoetis from $165.00 to $158.00 and set a “neutral” rating for the company in a research note on Monday, October 20th. Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Finally, Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Four research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $195.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.